MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/ppa.s628920

Медицинская библиотека · Patient preference and adherence · 2026

Health-Related Quality of Life Among Patients with Treatment-Resistant Schizophrenia Receiving Clozapine-Based Therapy in South Kalimantan, Indonesia.

Erlianti Karina, Alfaqeeh Mohammed, Puspitasari Irma Melyani, Purba Fredrick Dermawan, Suwantika Auliya A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Treatment-resistant schizophrenia (TRS) is associated with impairment and reduced health-related quality of life (HRQoL). Although clozapine is the standard treatment for TRS, evidence regarding HRQoL across clozapine-based regimens in low- and middle-income settings remains limited. This study evaluated HRQoL among clinically stable outpatients with TRS receiving clozapine-based therapy in Indonesia.

METHODS

A cross-sectional study was conducted at the mental hospital between November 2024 and January 2025. Participants (n = 147) received clozapine as monotherapy or in combination with first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), or both. HRQoL was assessed using the Indonesian EQ-5D-5L and EQ-VAS. Differences across regimens were assessed using the Kruskal-Wallis test, followed by Mann-Whitney U pairwise comparisons with Bonferroni correction. Spearman's rank correlation assessed the association between EQ-5D-5L utility and EQ-VAS. Adjusted general linear models examined associations between treatment regimen and HRQoL after accounting for sociodemographic and characteristics.

RESULTS

Mean EQ-5D-5L utility and EQ-VAS scores were 0.804 ± 0.10 and 73.64 ± 9.46. Mobility was the least affected domain (95.2% reporting no problems), whereas impairment was observed in usual activities and anxiety/depression. EQ-5D-5L utility was positively correlated with EQ-VAS (Spearman's ρ = 0.606, p < 0.001). Both utility and EQ-VAS differed across treatment regimens (both p < 0.001), with the clozapine + FGA group showing the lowest scores. After adjustment, treatment regimen remained associated with utility (p = 0.002) and EQ-VAS (p < 0.001).

CONCLUSION

Clinically stable outpatients with TRS receiving clozapine-based therapy demonstrated favorable HRQoL, although impairments persisted in psychological well-being and daily functioning. Treatment regimen remained associated with both HRQoL measures after adjustment. These findings represent associations rather than causal effects and support individualized treatment selection, monitoring of treatment burden, and integration of psychosocial interventions.

Для цитирования: Erlianti Karina, Alfaqeeh Mohammed, Puspitasari Irma Melyani, Purba Fredrick Dermawan, Suwantika Auliya A. Health-Related Quality of Life Among Patients with Treatment-Resistant Schizophrenia Receiving Clozapine-Based Therapy in South Kalimantan, Indonesia.. Patient preference and adherence. 2026. DOI: 10.2147/ppa.s628920.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.